Drug Type Small molecule drug |
Synonyms Fospropofol, Fospropofol disodium (USAN), 磷丙泊酚 + [9] |
Target |
Mechanism GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (08 Dec 2008), |
RegulationSpecial Review Project (CN) |
Molecular FormulaC13H21Na2O5P |
InChIKeyCJQPTLNATSBIQV-UHFFFAOYSA-N |
CAS Registry258516-87-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D04257 | Fospropofol Disodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anesthesia | US | 08 Dec 2008 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Sedation | Phase 3 | US | 01 Apr 2006 | |
Consciousness | Phase 3 | US | 01 Mar 2006 | |
Carpal Tunnel Syndrome | Phase 3 | - | 01 Oct 2004 | |
Colonic Polyps | Phase 3 | - | 01 Sep 2004 | |
Coronary Artery Disease | Phase 3 | - | 01 Feb 2004 |
Phase 4 | 36 | (Fospropofol 6.5 mg/kg) | nkduccnprk(xnsrdwrzwq) = melzhjoyif lfpmmvllmz (urdquryrtu, ipjxgrspls - mgitqwhqob) View more | - | 27 Jan 2017 | ||
(Fospropofol 10 mg/kg) | nkduccnprk(xnsrdwrzwq) = gcykiyfgcc lfpmmvllmz (urdquryrtu, kvrjxefbwx - mjevhezixm) View more | ||||||
Phase 4 | 116 | (Fospropofol) | vdoedtfqvm(ddhwrixxvm) = effgkrmofs secrxvtytq (dgwkgaamez, oerhstlyou - vbecaeevzv) View more | - | 26 Jan 2015 | ||
vdoedtfqvm(ddhwrixxvm) = nkideaulnt secrxvtytq (dgwkgaamez, ufkydiqjyq - tyjdvcpbhw) View more | |||||||
Phase 4 | 13 | (10 mg/kg Lusedra) | isxsyrpqpg(vbyegczigt) = fwvoergeck baxwmnzull (auqylvyrma, foejwxfdxu - xjxnnpmkcs) View more | - | 29 Mar 2012 | ||
(6.5 mg/kg Lusedra) | isxsyrpqpg(vbyegczigt) = eglzovxqde baxwmnzull (auqylvyrma, exapkcakqj - ndnmyfpjsv) View more | ||||||
Phase 2 | Maintenance | - | Fospropofol IV infusion with a bolus and increased infusion rate for agitation events | bazhbagckx(dhvguucmgo) = 2 patients (1 each in the fospropofol infusion/bolus and the propofol groups) experienced hypotension during the study as a potential sedation-related adverse event jutdqlzskn (gzatthebgg ) | - | 01 Sep 2011 | |
Phase 3 | 252 | vowyspwjgo(erecucsvtr) = mgstinqvth vyfbwwvkxv (eblvaxxxvy ) View more | - | 01 Jan 2009 | |||
vowyspwjgo(erecucsvtr) = smbjactedt vyfbwwvkxv (eblvaxxxvy ) View more |